Abstract
In the landscape of contemporary medicine, statins stand out as a cornerstone in the prevention and management of atherosclerotic cardiovascular diseases. By inhibiting the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase enzyme, statins effectively lower cholesterol levels, thus mitigating the risk of heart attacks and strokes.1 Despite their widespread adoption and generally well-tolerated nature, the clinical panorama of statin therapy is occasionally marred by side effects, including muscle-related adverse events. These range from relatively common and benign myalgias to the rare and severe statin-induced necrotizing autoimmune myopathy (SINAM), a condition marked by muscle weakness and profoundly elevated levels of creatine kinase (CK) that persist even after the discontinuation of the offending statin2 (Table 1).
Recommended Citation
Teichner, MS, Eric M. and Ashok, MS, Arjun B.
(2024)
"Statin-Induced Necrotizing Autoimmune Myopathy: A Case Report,"
The Medicine Forum: Vol. 25, Article 15.
DOI: https://doi.org/10.29046/TMF.025.1.014
Available at:
https://jdc.jefferson.edu/tmf/vol25/iss1/15
